Login or Register to unlock everything MedSchool has to offer!
Monoclonal Antibodies

Anti-PD-L1 Antibodies

    IV infusion
    IV infusion
    IV infusion


    • Mechanism of Action

    • Monoclonal antibodies directed against PD-L1, an inhibitory molecule expressed on certain tumour cells.
    • PD-L1 and PD-L2 are ligands that bind to PD-1 receptors on activated lymphocytes and inhibit T cell receptor signalling, downregulating immune responses and promoting tolerance.
    • Binding of anti-PD-L1 monoclonal antibodies leaves the ligand unable to bind to PD-1, and therefore stimulates an ongoing immune response.
  • PD-L2 is not inhibited, allowing PD-1 / PD-L2 mediated inhibitory signals to continue

Clinical Use

    • Indications

    • Locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression post chemotherapy / targeted therapy (atezolizumab)
    • Locally advanced non-small cell lung cancer (NSCLC) without progression post chemoradiotherapy (durvalumab)
    • Locally advanced or metastatic urothelial carcinoma with progression post platnium-based chemotherapy (durvalumab)
    • Metastatic Merkel cell carcinoma (avelumab)
    • Adverse Effects

    • Immune-Related

    • Endocrinopathies - thyroiditis, adrenalitis, hypophysitis, diabetes mellitus
    • Pulmonary toxicity - pneumonitis
    • Hepatotoxicity - LFT derangement, hepatitis
    • GI toxicity - colitis
    • Rheumatological - flares of previous disease
    • Skin - rash, pruritis
    • Other

    • Fatigue
    • Anorexia
    • Headache
    • Dizziness
    • Nausea / vomiting / diarrhoea
    • Thrombocytopaenia
Last updated on November 8th, 2018


 Bou-Assaly W, Mukherji S. Cetuximab (erbitux). American Journal of Neuroradiology. 2010 Apr 1;31(4):626-7. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. InSeminars in oncology 2006 Oct 31 (Vol. 33, pp. S1-S7). WB Saunders. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E. Pembrolizumab for the treatment of non–small-cell lung cancer. New England Journal of Medicine. 2015 May 21;372(21):2018-28. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2003 Nov 15;98(10):2095-104. Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M, Hoos A. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. Journal of Clinical Oncology. 2011 May 20;29(15_suppl):8583-. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Scientific reports. 2017 Jul 17;7(1):5532. Maloney DG. Mechanism of action of rituximab. Anti-cancer drugs. 2001 Jun;12:S1-4. Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia. 2006 Feb 1;20(2):272-9. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cs?szi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New England Journal of Medicine. 2016 Nov 10;375(19):1823-33. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer.Nature reviews. Cancer. 2012;12:278-287. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer biotherapy & radiopharmaceuticals. 2010 Dec 1;25(6):601-13. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine. 2012 Nov 8;367(19):1783-91.